Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Breathable insole ODM development China

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Graphene cushion OEM factory in China

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Vietnam insole ODM design and production

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Custom graphene foam processing factory Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan neck support pillow OEM factory

MIT researchers have created a tissue model that allows them model drug delivery to brain tumors. Tumor cells (green) are surrounded by endothelial cells (purple). Credit: Cynthia Hajal and Roger D. Kamm (MIT), edited by Chris Straehla Tested using a new brain tissue model, the tiny particles may be able to deliver chemotherapy drugs for glioblastoma, a fast-growing and aggressive type of cancer. Currently, there are very few good treatment options for glioblastoma, an aggressive type of brain cancer with a high fatality rate. One reason that the disease is so difficult to treat is that most chemotherapy drugs can’t penetrate the blood vessels that surround the brain. A team of scientists at MIT is now developing drug-carrying nanoparticles that appear to get into the brain more efficiently than drugs given on their own. Using a human tissue model they designed, which accurately replicates the blood-brain barrier, the scientists showed that the particles could get into tumors and kill glioblastoma cells. In the past, many potential glioblastoma treatments have shown success in animal models but then ended up failing in clinical trials. This suggests that a better kind of modeling is needed, says Joelle Straehla, the Charles W. and Jennifer C. Johnson Clinical Investigator at MIT’s Koch Institute for Integrative Cancer Research, an instructor at Harvard Medical School, and a pediatric oncologist at Dana-Farber Cancer Institute. “We are hoping that by testing these nanoparticles in a much more realistic model, we can cut out a lot of the time and energy that’s wasted trying things in the clinic that don’t work,” she says. “Unfortunately, for this type of brain tumor, there have been hundreds of trials that have had negative results.” Straehla and Cynthia Hajal SM ’18, PhD ’21, a postdoc at Dana-Farber, are the lead authors of the study, which was published on June 1, 2022, in the Proceedings of the National Academy of Sciences. Paula Hammond, an MIT Institute Professor, head of the Department of Chemical Engineering, and a member of the Koch Institute; and Roger Kamm, the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, are the senior authors of the paper. Modeling the Blood-Brain Barrier Several years ago, Kamm’s lab began working on a microfluidic model of the brain and the blood vessels that make up the blood-brain barrier. Because the brain is such a vital organ, the blood vessels surrounding the brain are much more restrictive than other blood vessels in the body, to keep out potentially harmful molecules. To mimic that structure in a tissue model, the researchers grew patient-derived glioblastoma cells in a microfluidic device. Then, they used human endothelial cells to grow blood vessels in tiny tubes surrounding the sphere of tumor cells. The model also includes pericytes and astrocytes, two cell types that are involved in transporting molecules across the blood-brain barrier. While Hajal was working on this model as a graduate student in Kamm’s lab, she got connected with Straehla, then a postdoc in Hammond’s lab, who was interested in finding new ways to model nanoparticle drug delivery to the brain. Getting drugs across the blood-brain barrier is critical for improving treatment for glioblastoma, which is usually treated with a combination of surgery, radiation, and the oral chemotherapy temozolomide. The five-year survival rate for the disease is less than 10 percent. Hammond’s lab pioneered a technique called layer-by-layer assembly, which they can use to create surface-functionalized nanoparticles that carry drugs in their core. The particles that the researchers developed for this study are coated with a peptide called AP2, which has been shown in previous work to help nanoparticles get through the blood-brain barrier. However, without accurate models, it was difficult to study how the peptides helped with transport across blood vessels and into tumor cells. When the researchers delivered these nanoparticles to tissue models of both glioblastoma and healthy brain tissue, they found that the particles coated with the AP2 peptide were much better at penetrating the vessels surrounding the tumors. They also showed that the transport occurred due to binding a receptor called LRP1, which is more abundant near tumors than in normal brain vessels. The researchers then filled the particles with cisplatin, a commonly used chemotherapy drug. When these particles were coated with the targeting peptide, they were able to effectively kill glioblastoma tumor cells in the tissue model. However, particles that didn’t have the peptides ended up damaging the healthy blood vessels instead of targeting the tumors. “We saw increased cell death in tumors that were treated with the peptide-coated nanoparticle compared to the bare nanoparticles or free drug. Those coated particles showed more specificity of killing the tumor, versus killing everything in a nonspecific way,” Hajal says. More Effective Particles The researchers then tried delivering the nanoparticles to mice, using a specialized surgical microscope to track the nanoparticles moving through the brain. They found that the particles’ ability to cross the blood-brain barrier was very similar to what they had seen in their human tissue model. They also showed that coated nanoparticles carrying cisplatin could slow down tumor growth in mice, but the effect wasn’t as strong as what they saw in the tissue model. This might be because the tumors were in a more advanced stage, the researchers say. They now hope to test other drugs, carried by a variety of nanoparticles, to see which might have the greatest effect. They also plan to use their approach to model other types of brain tumors. “This is a model that we could use to design more effective nanoparticles,” Straehla says. “We’ve only tested one type of brain tumor, but we really want to expand and test this with a lot of others, especially rare tumors that are difficult to study because there may not be as many samples available.” The researchers described the method they used to create the brain tissue model in a recent Nature Protocols paper, so that other labs can also use it. Reference: “A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles” by Joelle P. Straehla, Cynthia Hajal, Hannah C. Safford, Giovanni S. Offeddu, Natalie Boehnke, Tamara G. Dacoba, Jeffrey Wyckoff, Roger D. Kamm and Paula T. Hammond, 1 June 2022, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2118697119 The research was funded, in part, by a Cooperative Agreement Award from the National Cancer Institute, a Horizon Award from the Department of Defense Peer Reviewed Cancer Research Program, a Cancer Research UK Brain Tumour Award, a Ludwig Center for Molecular Oncology Graduate Fellowship, the Rally Foundation for Childhood Cancer Research/The Truth 365, the Helen Gurley Brown Presidential Initiative, and the Koch Institute Support (core) Grant from the National Cancer Institute.

Scientists have published the first complete, gapless sequence of a human genome, two decades after the Human Genome Project produced the first draft human genome sequence. Credit: Ernesto del Aguila III, NHGRI The full, uninterrupted sequence of the human genome has been achieved by the T2T consortium, providing a detailed view of human DNA that greatly enhances our understanding of genetic variations and their implications for diseases. Scientists have published the first complete, gapless sequence of a human genome, two decades after the Human Genome Project produced the first draft human genome sequence. According to researchers, having a complete, gap-free sequence of the roughly 3 billion bases (or “letters”) in our DNA is critical for understanding the full spectrum of human genomic variation and for understanding the genetic contributions to certain diseases. The work was done by the Telomere to Telomere (T2T) consortium, which included leadership from researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health; University of California, Santa Cruz; and University of Washington, Seattle. NHGRI was the primary funder for the study. Analyses of the complete genome sequence will significantly add to our knowledge of chromosomes, including more accurate maps for five chromosome arms, which opens new lines of research. This helps answer basic biology questions about how chromosomes properly segregate and divide. The T2T consortium used the now-complete genome sequence as a reference to discover more than 2 million additional variants in the human genome. These studies provide more accurate information about the genomic variants within 622 medically relevant genes. “Generating a truly complete human genome sequence represents an incredible scientific achievement, providing the first comprehensive view of our DNA blueprint,” said Eric Green, M.D., Ph.D., director of NHGRI. “This foundational information will strengthen the many ongoing efforts to understand all the functional nuances of the human genome, which in turn will empower genetic studies of human disease.” The now-complete human genome sequence will be particularly valuable for studies that aim to establish comprehensive views of human genomic variation, or how people’s DNA differs. Such insights are vital for understanding the genetic contributions to certain diseases and for using genome sequence as a routine part of clinical care in the future. Many research groups have already started using a pre-release version of the complete human genome sequence for their research. Technological Innovations in Genome Sequencing The full sequencing builds upon the work of the Human Genome Project, which mapped about 92% of the genome, and research undertaken since then. Thousands of researchers have developed better laboratory tools, computational methods, and strategic approaches to decipher the complex sequence. Six papers encompassing the completed sequence appear in Science, along with companion papers in several other journals. That last 8% includes numerous genes and repetitive DNA and is comparable in size to an entire chromosome. Researchers generated the complete genome sequence using a special cell line that has two identical copies of each chromosome, unlike most human cells, which carry two slightly different copies. The researchers noted that most of the newly added DNA sequences were near the repetitive telomeres (long, trailing ends of each chromosome) and centromeres (dense middle sections of each chromosome). “Ever since we had the first draft human genome sequence, determining the exact sequence of complex genomic regions has been challenging,” said Evan Eichler, Ph.D., researcher at the University of Washington School of Medicine and T2T consortium co-chair. “I am thrilled that we got the job done. The complete blueprint is going to revolutionize the way we think about human genomic variation, disease and evolution.” The cost of sequencing a human genome using “short-read” technologies, which provide several hundred bases of DNA sequence at a time, is only a few hundred dollars, having fallen significantly since the end of the Human Genome Project. However, using these short-read methods alone still leaves some gaps in assembled genome sequences. The massive drop in DNA sequencing costs comes hand-in-hand with increased investments in new DNA sequencing technologies to generate longer DNA sequence reads without compromising the accuracy. Breakthroughs with Long-Read DNA Sequencing Technologies Over the past decade, two new DNA sequencing technologies emerged that produced much longer sequence reads. The Oxford Nanopore DNA sequencing method can read up to 1 million DNA letters in a single read with modest accuracy, while the PacBio HiFi DNA sequencing method can read about 20,000 letters with nearly perfect accuracy. Researchers in the T2T consortium used both DNA sequencing methods to generate the complete human genome sequence. “Using long-read methods, we have made breakthroughs in our understanding of the most difficult, repeat-rich parts of the human genome,” says Karen Miga, Ph.D., a co-chair of the T2T consortium whose research group at the University of California, Santa Cruz is funded by NHGRI. “This complete human genome sequence has already provided new insight into genome biology, and I look forward to the next decade of discoveries about these newly revealed regions.” According to consortium co-chair Adam Phillippy, Ph.D., whose research group at NHGRI led the finishing effort, sequencing a person’s entire genome should get less expensive and more straightforward in the coming years. “In the future, when someone has their genome sequenced, we will be able to identify all of the variants in their DNA and use that information to better guide their healthcare,” Phillippy said. “Truly finishing the human genome sequence was like putting on a new pair of glasses. Now that we can clearly see everything, we are one step closer to understanding what it all means.” Many early-career researchers and trainees played pivotal roles, including researchers from Johns Hopkins University, Baltimore; University of Connecticut, Storrs; University of California, Davis; Howard Hughes Medical Institute, Chevy Chase, Maryland; and the National Institute of Standards and Technology, Gaithersburg, Maryland. The package of six papers reporting this accomplishment appears in today’s issue of Science, along with companion papers in several other journals. For more on this research, see Hidden Regions Revealed in First Complete Sequence of a Human Genome. Reference: “The complete sequence of a human genome” by Sergey Nurk, Sergey Koren, Arang Rhie, Mikko Rautiainen, Andrey V. Bzikadze, Alla Mikheenko, Mitchell R. Vollger, Nicolas Altemose, Lev Uralsky, Ariel Gershman, Sergey Aganezov, Savannah J. Hoyt, Mark Diekhans, Glennis A. Logsdon, Michael Alonge, Stylianos E. Antonarakis, Matthew Borchers, Gerard G. Bouffard, Shelise Y. Brooks, Gina V. Caldas, Nae-Chyun Chen, Haoyu Cheng, Chen-Shan Chin, William Chow, Leonardo G. de Lima, Philip C. Dishuck, Richard Durbin, Tatiana Dvorkina, Ian T. Fiddes, Giulio Formenti, Robert S. Fulton, Arkarachai Fungtammasan, Erik Garrison, Patrick G. S. Grady, Tina A. Graves-Lindsay, Ira M. Hall, Nancy F. Hansen, Gabrielle A. Hartley, Marina Haukness, Kerstin Howe, Michael W. Hunkapiller, Chirag Jain, Miten Jain, Erich D. Jarvis, Peter Kerpedjiev, Melanie Kirsche, Mikhail Kolmogorov, Jonas Korlach, Milinn Kremitzki, Heng Li, Valerie V. Maduro, Tobias Marschall, Ann M. McCartney, Jennifer McDaniel, Danny E. Miller, James C. Mullikin, Eugene W. Myers, Nathan D. Olson, Benedict Paten, Paul Peluso, Pavel A. Pevzner, David Porubsky, Tamara Potapova, Evgeny I. Rogaev, Jeffrey A. Rosenfeld, Steven L. Salzberg, Valerie A. Schneider, Fritz J. Sedlazeck, Kishwar Shafin, Colin J. Shew, Alaina Shumate, Ying Sims, Arian F. A. Smit, Daniela C. Soto, Ivan Sovic, Jessica M. Storer, Aaron Streets, Beth A. Sullivan, Françoise Thibaud-Nissen, James Torrance, Justin Wagner, Brian P. Walenz, Aaron Wenger, Jonathan M. D. Wood, Chunlin Xiao, Stephanie M. Yan, Alice C. Young, Samantha Zarate, Urvashi Surti, Rajiv C. McCoy, Megan Y. Dennis, Ivan A. Alexandrov, Jennifer L. Gerton, Rachel J. O’Neill, Winston Timp, Justin M. Zook, Michael C. Schatz, Evan E. Eichler, Karen H. Miga and Adam M. Phillippy, 31 March 2022, Science. DOI: 10.1126/science.abj6987

Researchers from UMD found that the same gene for expressing a red fluorescent protein is always expressed (ON), when it is inherited from the mother, but when inherited from the father can lose expression (turn OFF) forever if the mother lacks the gene. Credit: Antony Jose/UMD University of Maryland scientists discover that match matters: The right combination of parents in nematode worms can turn a gene off indefinitely. Evidence suggests that what happens in one generation — diet, toxin exposure, trauma, fear — can have lasting effects on future generations. Scientists believe these effects result from epigenetic changes that occur in response to the environment and turn genes on or off without altering the genome or DNA sequence. But how these changes are passed down through generations has not been understood, in part, because scientists have not had a simple way to study the phenomenon. A new study by researchers at the University of Maryland provides a potential tool for unraveling the mystery of how experiences can cause inheritable changes to an animal’s biology. By mating nematode worms, they produced permanent epigenetic changes that lasted for more than 300 generations. The research was published on July 9, 2021, in the journal Nature Communications. “There’s a lot of interest in heritable epigenetics,” said Antony Jose, associate professor of cell biology and molecular genetics at UMD and senior author of the study. “But getting clear answers is difficult. For instance, if I’m on some diet today, how does that affect my children and grandchildren and so on? No one knows, because so many different variables are involved. But we’ve found this very simple method, through mating, to turn off a single gene for multiple generations. And that gives us a huge opportunity to study how these stable epigenetic changes occur.” In the new study, Jose and his team found while breeding nematode worms that some matings led to epigenetic changes in offspring that continued to be passed down through as many generations as the scientists continued to breed them. This discovery will enable scientists to explore how epigenetic changes are passed to future generations and what characteristics make genes susceptible to permanent epigenetic changes. Jose and his team began this work in 2013, while working with nematode worms, Caenorhabditis elegans (C. elegans), a species often used as a model for understanding animal biology. The scientists noticed that worms bred to carry a gene they called T, which produces fluorescent proteins, sometimes glowed and sometimes didn’t. This was puzzling because the glowers and the non-glowers had nearly identical DNA. “Everything began when we stumbled upon a rare gene that underwent permanent change for hundreds of generations just by mating. We could have easily missed it,” said Sindhuja Devanapally (Ph.D. ’18, biological sciences), a co-lead author of the study who is now a postdoctoral fellow at Columbia University. To understand the phenomenon better, the researchers conducted breeding experiments in which only the mother or the father carried the fluorescent gene. The team expected that no matter which parent carried the gene, the offspring would glow. Instead, they found that when the mother carried the fluorescent gene, the offspring always glowed, meaning the gene was always turned on. But when the father carried the gene, the offspring usually weakly glowed or did not glow at all. “We found that there are these RNA-based signals controlling gene expression,” Jose said. “Some of these signals silence the gene and some of them are protective signals that prevent silencing. These signals are duking it out as the offspring develop. When the gene comes from the mother, the protective signal always wins, but when the gene comes from the father, the silencing signal almost always wins.” When the silencing signal wins, the gene is silenced for good, or for at least 300 generations, which is how long Jose and his colleagues followed their laboratory-bred worms. Previous examples of epigenetic changes were more complex or they did not last more than a couple of generations. The researchers don’t yet know why the silencing signal only wins some of the time, but this new finding puts them in a much better position to explore the details of epigenetic inheritance than ever before. “While we’ve found a set of genes that can be silenced almost permanently, most other genes are not affected the same way,” said the study’s other co-lead author, Pravrutha Raman (Ph.D. ’19, biological sciences), who is now a postdoctoral fellow at Fred Hutchinson Cancer Research Center. “After silencing, they bounce back and become expressed in future generations.” With their new findings, the researchers now believe some genes could be more vulnerable to permanent epigenetic change while other genes recover within a few generations. Although studies in worms are not the same as in humans, the research provides a window into biological processes that are likely shared, at least in part, by all animals. “The two big advantages we now have from this work are that this long-lasting epigenetic change is easy to induce through mating, and that it occurs at the level of a single gene,” Jose said. “Now we can manipulate this gene and control everything about it, which will allow us to determine what characteristics make a gene susceptible or resistant to heritable epigenetic change.” Jose and his colleagues expect that future studies may one day help scientists identify human genes that are vulnerable to long-lasting epigenetic changes. Reference: “Mating can initiate stable RNA silencing that overcomes epigenetic recovery” by Sindhuja Devanapally, Pravrutha Raman, Mary Chey, Samual Allgood, Farida Ettefa, Maïgane Diop, Yixin Lin, Yongyi E. Cho and Antony M. Jose, 9 July 2021, Nature Communications. DOI: 10.1038/s41467-021-24053-4 This work was supported by the National Institutes of Health (Award Nos. R01GM111457 and R01GM124356). The content of this article does not necessarily reflect the views of this organization. Other authors of the study from UMD include biological sciences Ph.D. candidate Mary Chey, Samual Allgood (B.S. ’15, biological sciences), Farida Ettefa (B.S. ’18, biochemistry), Maïgane Diop (B.S. ’20, biological sciences), Yixin Lin (B.S. ’19, biological sciences; M.Ed. ’20), Yongyi E Cho (B.S. ’20, biological sciences; B.A. ’20, philosophy).

DVDV1551RTWW78V